Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1568
Title: Developments in oligometastatic hormone-sensitive prostate cancer.
Authors: Stuchbery, Ryan
Corcoran, Niall
Hovens, Christopher
Other Authors: Chow, Ken
McCoy, Patrick
Keywords: Oligometastases
Metastasis
Prostate Cancer
Hormone Sensitive
Genetics
Molecular
Disease Management
Systemic Therapies
Aggressive Treatments
Cancer Progression
Australian Prostate Cancer Research Centre Epworth HealthCare, Victoria, Australia
Issue Date: Oct-2018
Publisher: Springer
Citation: 10.1007/s00345-018-2542-x
Abstract: PURPOSE: To review the current understanding and recent developments regarding the concept of oligometastases in hormone-sensitive prostate cancer. METHODS: A comprehensive literature search of electronic databases, including PubMed and Embase was conducted for the search term 'oligometastases' in combinations with 'prostate cancer', 'hormone sensitive', 'genetics', and 'molecular'. All articles relating to these search terms have been taken into account. RESULTS: Prostate cancer remains a major cause of morbidity and mortality worldwide. The majority of these cancer-related deaths result from metastases. Currently, there is a dichotomy in prostate cancer management where it is only deemed curable if it is localized, while any signs of metastasis relegate patients to systemic therapies to delay their inevitable death. A growing body of evidence supports the notion that aggressive treatments during the stable 'oligometastatic' state can have significant clinical benefits and potentially 'reset' prostate cancer to an earlier time point in cancer progression. This concept of oligometastases has been adopted in other cancer settings such as colorectal and non-small-cell lung cancers. CONCLUSION: Multiple clinical and molecular biological studies have been influential in the support of a stable state in metastatic cancer progression coined 'oligometastases'. As our understanding of oligometastases in hormone-sensitive prostate cancer develops, we will be able to molecularly define the oligometastatic state and develop clinically available diagnostic tests. In doing so, prostate cancer patients will experience significant clinical benefits and the burden of prostate cancer worldwide will likely be reduced.
URI: http://hdl.handle.net/11434/1568
DOI: Department of Urology, Royal Melbourne Hospital, Parkville, Australia
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/30382379
ISSN: 0724-4983
1433-8726
Journal Title: World Journal of Urology
Type: Journal Article
Affiliated Organisations: Department of Surgery, The University of Melbourne, Parkville, Australia
Department of Urology, Royal Melbourne Hospital, Parkville, Australia
Type of Clinical Study or Trial: Literature Review
Appears in Collections:Epworth Prostate Centre

Files in This Item:
There are no files associated with this item.


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.